AMITRIPTYLINE HYDROCHLORIDE | A215376 | RUBICON RESEARCH LTD
No patent or exclusivity listings for this strength.
Rubicon Research's amitriptyline hydrochloride (NDA 215376, supplement 004) received an AB therapeutic equivalence rating, upgrading from its previous BX designation.
Old: BX
New: AB
Rubicon Research's Amitriptyline Hydrochloride (NDA 215376) therapeutic equivalence code changed from BX to AB, indicating the FDA now considers it therapeutically equivalent to reference-listed drugs.
Old: BX
New: AB
Rubicon Research's amitriptyline hydrochloride (NDA 215376, supplement 003) therapeutic equivalence rating changed from BX to AB, indicating the product is now considered therapeutically equivalent to the reference standard.
Old: BX
New: AB
Rubicon Research's Amitriptyline Hydrochloride (NDA 215376) therapeutic equivalence code changed from BX to AB, indicating the product now meets bioequivalence standards for generic substitution.
Old: BX
New: AB
Rubicon Research's amitriptyline hydrochloride (NDA 215376, supplement 006) therapeutic equivalence code changed from BX to AB, indicating the product is now considered therapeutically equivalent to the reference listed drug.
Old: BX
New: AB
Rubicon Research's Amitriptyline Hydrochloride (NDA 215376) therapeutic equivalence code changed from BX to AB, indicating the product now meets bioequivalence standards for generic substitution.
Old: BX
New: AB